The radiation oncologist and chief medical executive at MD Anderson Cancer Center has not worked in government previously.

The treatment, Trikafta, increases lung function in most patients with the disease—but comes with a hefty price tag.

The Albert Einstein College of Medicine neuroscientist has revealed surprising functions of the brain region, such as its role in the brain’s rewards circuits and in addiction.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

The agency plans to stop funding virtually all toxicology studies in mammals by 2035.

The FDA and the university have audited Kang Zhang for breaches in bioethics and a failure to follow research protocols.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.

Two coauthors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them.